AU2003295784B2 - Composition and method for treating lupus nephritis - Google Patents

Composition and method for treating lupus nephritis Download PDF

Info

Publication number
AU2003295784B2
AU2003295784B2 AU2003295784A AU2003295784A AU2003295784B2 AU 2003295784 B2 AU2003295784 B2 AU 2003295784B2 AU 2003295784 A AU2003295784 A AU 2003295784A AU 2003295784 A AU2003295784 A AU 2003295784A AU 2003295784 B2 AU2003295784 B2 AU 2003295784B2
Authority
AU
Australia
Prior art keywords
polypeptide
nucleic acid
bflp
protein
bflp1698
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003295784A
Other languages
English (en)
Other versions
AU2003295784A1 (en
Inventor
William M. Mounts
Margot O'toole
Negin Shojaee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2003295784A1 publication Critical patent/AU2003295784A1/en
Application granted granted Critical
Publication of AU2003295784B2 publication Critical patent/AU2003295784B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003295784A 2002-11-21 2003-11-21 Composition and method for treating lupus nephritis Ceased AU2003295784B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42806502P 2002-11-21 2002-11-21
US60/428,065 2002-11-21
PCT/US2003/037317 WO2004047740A2 (en) 2002-11-21 2003-11-21 Composition and method for treating lupus nephritis

Publications (2)

Publication Number Publication Date
AU2003295784A1 AU2003295784A1 (en) 2004-06-18
AU2003295784B2 true AU2003295784B2 (en) 2009-06-11

Family

ID=32393343

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003295784A Ceased AU2003295784B2 (en) 2002-11-21 2003-11-21 Composition and method for treating lupus nephritis

Country Status (9)

Country Link
US (2) US20050119208A1 (enExample)
EP (1) EP1563056A4 (enExample)
JP (1) JP2006516191A (enExample)
CN (1) CN1738896A (enExample)
AU (1) AU2003295784B2 (enExample)
BR (1) BR0316467A (enExample)
CA (1) CA2504561A1 (enExample)
MX (1) MXPA05005284A (enExample)
WO (1) WO2004047740A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020226960A1 (en) 2019-05-03 2020-11-12 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059260A2 (en) * 2000-11-17 2002-08-01 Hyseq, Inc. Nucleic acids and polypeptides
US20020137077A1 (en) * 2000-10-25 2002-09-26 Hopkins Christopher M. Genes regulated in activated T cells
WO2002081731A2 (en) * 2001-01-30 2002-10-17 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002092759A2 (en) * 2001-04-27 2002-11-21 Incyte Genomics, Inc. Molecules for disease detection and treatment
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137077A1 (en) * 2000-10-25 2002-09-26 Hopkins Christopher M. Genes regulated in activated T cells
WO2002059260A2 (en) * 2000-11-17 2002-08-01 Hyseq, Inc. Nucleic acids and polypeptides
WO2002081731A2 (en) * 2001-01-30 2002-10-17 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002092759A2 (en) * 2001-04-27 2002-11-21 Incyte Genomics, Inc. Molecules for disease detection and treatment
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Uniprot Accession: NoQ9VFS6 *

Also Published As

Publication number Publication date
EP1563056A4 (en) 2005-12-28
BR0316467A (pt) 2005-10-11
EP1563056A2 (en) 2005-08-17
WO2004047740A3 (en) 2005-02-17
JP2006516191A (ja) 2006-06-29
US20050119208A1 (en) 2005-06-02
US7667020B2 (en) 2010-02-23
CA2504561A1 (en) 2004-06-10
WO2004047740A2 (en) 2004-06-10
CN1738896A (zh) 2006-02-22
US20080009008A1 (en) 2008-01-10
MXPA05005284A (es) 2005-07-25
AU2003295784A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
US20090098132A1 (en) Composition and method for treating lupus nephritis
US20020098540A1 (en) Novel polypeptides, and nucleic acids encoding the same
US20070196370A1 (en) Type 2 cytokine receptor and nucleic acids encoding same
JP2004534518A (ja) タンパク質およびそれをコードする核酸
AU2002249948A1 (en) Type 2 cytokine receptor and nucleic acids encoding same
JP2009060899A (ja) ２型サイトカインレセプターおよびそれをコードする核酸
US7667020B2 (en) Composition and method for treating lupus nephritis
WO2002099116A2 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030100491A1 (en) Novel proteins and nucleic acids encoding same
JP2003245076A (ja) 新規タンパク質およびそのｄｎａ
JP2001029090A (ja) 新規ポリペプチド
WO2002033071A1 (fr) Polypeptides analogues a la survivine et leurs adn
WO2006034007A2 (en) Methods of treating metabolic disorders by modulation of salt-inducible serine/threonine kinase 2
US20020132317A1 (en) Novel interferon-induced tetraspan protein and nucleic acids encoding same
JP2004121246A (ja) 神経変性疾患の予防・治療剤
WO2002036632A2 (en) Single nucleotide polymorphisms in nucleic acids encoding human olfactory receptor-like polypeptides
JP2000053700A (ja) 新規タンパク質およびそのｄｎａ
JP2004057169A (ja) 新規タンパク質およびそのｄｎａ
JP2004313173A (ja) 新規タンパク質およびそのｄｎａ
JP2004024241A (ja) 新規タンパク質およびそのｄｎａ
JP2002355062A (ja) サバイビン類似ポリペプチドおよびそのｄｎａ
JP2004081196A (ja) 新規タンパク質およびそのｄｎａ
JP2004000117A (ja) 新規タンパク質およびそのｄｎａ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired